Clinical Trial

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Study acronym: GSBR-1290
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of aleniglipron at doses up to 240 mg once daily (QD) in participants with T2DM who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2).
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-28
notable Enrollment increased: 50 -> 58 participants 2026-04-28
notable Primary completion moved earlier: 2026-10 -> 2026-09 2026-04-28
minor Completion moved earlier: 2026-11 -> 2026-09 2026-04-28
Trial Details
NCT Number NCT07400588
Lead Sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss
Enrollment 58 participants
Start Date 2025-12-01
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-04-27